Drug Trial Radar · NCT06586242
Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
194
Planned (sponsor's estimate)
Start
Apr 3, 2023
Primary completion
Apr 2025
Study completion Apr 2036
Sponsor
- Lead sponsor
- Xijing HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a two arm, randomized, prospective, multicenter study on the perioperative treatment of locally advanced resectable esophageal cancer with penpulimab combined with anlotinib hydrochloride and chemotherapy.
Conditions
- Esophageal Cancer
Interventions
Penpulimab;Anlotinib;albumin paclitaxel;oxaliplatin;lobaplatinDrug
200mg, intravenous infusion, 30-60 minutes per infusion, once every 3 weeks, Penpulimab:administered on the first day of each cycle Anlotinib:Body weight \<60kg, 8mg Po, body weight ≥ 60kg, 10mg Po, D 1-14, q3w
Primary outcomes
What the sponsor says the trial is designed to measure.
- the Pathological complete response (PCR) rateTime frame: 2years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of the Air Force Medical University
Xi'an, Shaan'xi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.